XTalks

JANUARY 22, 2025

IXCHIQ is the only licensed chikungunya vaccine in the US for adults aged 18 and older at increased risk of exposure to the virus. The study included 754 adolescents, comparing immune responses and safety profiles between vaccine and placebo groups. Following the announcement, Valnevas stock rose by 1.4%.

Immune Response 59

Immune Response Vaccination Vaccine Trials 59

pharmaphorum

JANUARY 12, 2021

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. Soon-Shiong said that oral vaccines could have another key advantage as they stimulate mucosal, systemic and T-cell immune responses. “As

Licensing 120

Licensing Licensing Vaccination Vaccine 120

XTalks

JUNE 21, 2024

Dr. Bryan began his career at Schering-Plough, engaging in formulation and drug delivery. Unlike traditional therapies that act on the immune cascade after it has been initiated, Revolo’s treatments act at the very beginning of the immune response.

Development 52

Development Immune Response Drugs Regulation 52

XTalks

MAY 30, 2024

CIDP is a rare autoimmune disorder where the body’s immune system mistakenly attacks its own tissues. The exact cause of this immune response is unknown, and there appears to be no identifiable genetic predisposition to CIDP. Researchers estimate that the incidence of CIDP in the US ranges from 0.8

FDA Approval 40

FDA Approval Immune Response Trials Drug Delivery 40

Roots Analysis

JANUARY 27, 2025

In order to help circumvent these disadvantages, several drug delivery devices, which enable patients to self-administer drugs through subcutaneous route are now being developed. Moreover, protein-based drugs are also well tolerated inside the body, thereby reducing the chances of causing any immune response in the body.

Marketing 40

Marketing Drug Delivery Development Protein 40